IGI Logo

Alembic Pharmaceuticals is currently trading at Rs. 656.00, up by 5.60 points or 0.86% from its previous closing of Rs. 650.40 on the BSE.

The scrip opened at Rs. 644.35 and has touched a high and low of Rs. 662.15 and Rs. 642.85 respectively. So far 3159 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 863.10 on 12-Oct-2021 and a 52 week low of Rs. 641.80 on 23-Aug-2022.

Last one week high and low of the scrip stood at Rs. 665.50 and Rs. 641.80 respectively. The current market cap of the company is Rs. 12949.58 crore.

The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 18.09% and 12.30% respectively.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Chlorthalidone Tablets USP, 25 mg and 50 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Hygroton Tablets, 25 mg and 50 mg, of Sanofi Aventis US. LLC (Sanofi).

Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or; to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.

Chlorthalidone Tablets USP, 25 mg and 50 mg, have an estimated market size of $ 37 million for twelve months ending June, 2022 according to IQVIA. Alembic has a cumulative total of 171 ANDA approvals (147 final approvals and 24 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.